Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers Publisher



Arezumand R1 ; Alibakhshi A2 ; Ranjbari J2 ; Ramazani A3 ; Muyldermans S4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Biotechnology and Molecular Science, School of Medicine, North Khorasan University of Medical Sciences, Bojnourd, Iran
  2. 2. Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences, Zanjan, Iran
  4. 4. Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium

Source: Frontiers in Immunology Published:2017


Abstract

Solid cancers are dependent on angiogenesis for sustenance. The FDA approval of Bevacizumab in 2004 inspired many scientists to develop more inhibitors of angiogenesis. Although several monoclonal antibodies (mAbs) are being administered to successfully combat various pathologies, the complexity and large size of mAbs seem to narrow the therapeutic applications. To improve the performance of cancer therapeutics, including those blocking tumor angiogenesis, attractive strategies such as miniaturization of the antibodies have been introduced. Nanobodies (Nbs), small single-domain antigen-binding antibody fragments, are becoming promising therapeutic and diagnostic proteins in oncology due to their favorable unique structural and functional properties. This review focuses on the potential and state of the art of Nbs to inhibit the angiogenic process for therapy and the use of labeled Nbs for non-invasive in vivo imaging of the tumors. © 2017 Arezumand, Alibakhshi, Ranjbari, Ramazani and Muyldermans.
Related Docs
View other Related Docs
1. Targeted Cancer Therapy Through Antibody Fragments-Decorated Nanomedicines, Journal of Controlled Release (2017)
2. Targeted Drug Delivery Using Nanobodies to Deliver Effective Molecules to Breast Cancer Cells: The Most Attractive Application of Nanobodies, Cancer Cell International (2024)
3. Emerging Immunologic Approaches As Cancer Anti-Angiogenic Therapies, Clinical and Translational Oncology (2025)
4. An Overview on Display Systems (Phage, Bacterial, and Yeast Display) for Production of Anticancer Antibodies; Advantages and Disadvantages, International Journal of Biological Macromolecules (2022)
5. Nanobodies in Human Infections: Prevention, Detection, and Treatment, Immunological Investigations (2020)
6. Recombinant Nanobody Against Muc1 Tandem Repeats Inhibits Growth, Invasion, Metastasis, and Vascularization of Spontaneous Mouse Mammary Tumors, Molecular Oncology (2022)
7. Functional Study of a Camelid Single Domain Anti-Cd22 Antibody, International Journal of Peptide Research and Therapeutics (2020)
8. T Cell Engineered With a Novel Nanobody-Based Chimeric Antigen Receptor Against Vegfr2 As a Candidate for Tumor Immunotherapy, IUBMB Life (2019)
Experts (# of related papers)
View all Related Experts
Mohammad Hossein Modarressi (2)
Zargham Sepehrizadeh (2)
Other Related Docs
9. Radiolabeled Her2-Targeted Molecular Probes in Breast Cancer Imaging: Current Knowledge and Future Prospective, Naunyn-Schmiedeberg's Archives of Pharmacology (2025)
10. Identification and in Vitro Characterization of Novel Nanobodies Against Human Granulocyte Colony-Stimulating Factor Receptor to Provide Inhibition of G-Csf Function, Biomedicine and Pharmacotherapy (2017)
11. An In-Silico Approach to Find a Peptidomimetic Targeting Extracellular Domain of Her3 From a Her3 Nanobody, Computational Biology and Chemistry (2017)
12. Radiolabeling of the Mutant Form of Anti-Plgf Nanobody By99m Tc-Tricarbonyl, Iranian Journal of Pharmaceutical Research (2024)
13. Monoclonal Antibodies for Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
14. Construction of a Chimeric Antigen Receptor Bearing a Nanobody Against Prostate a Specific Membrane Antigen in Prostate Cancer, Journal of Cellular Biochemistry (2019)
15. Recent Advances in Non-Small Cell Lung Cancer Targeted Therapy; an Update Review, Cancer Cell International (2023)
16. Development of a Novel Human Scfv Against Egfr L2 Domain by Phage Display Technology, Current Pharmaceutical Design (2017)
17. Development and Clinical Application of Bispecific Antibody in the Treatment of Colorectal Cancer, Expert Review of Clinical Immunology (2020)
18. A Novel Tumor Inhibitory Hybridoma Monoclonal Antibody With Dual Specificity for Her3 and Her2, Current Research in Translational Medicine (2021)
19. Melatonin As an Angiogenesis Inhibitor to Combat Cancer: Mechanistic Evidence, Toxicology and Applied Pharmacology (2017)
20. Challenges Facing Antiangiogenesis Therapy: The Significant Role of Hypoxia-Inducible Factor and Met in Development of Resistance to Anti-Vascular Endothelial Growth Factor-Targeted Therapies, Journal of Cellular Physiology (2019)
21. Selection of Single-Chain Variable Fragments Specific for Mycobacterium Tuberculosis Esat-6 Antigen Using Ribosome Display, Iranian Journal of Basic Medical Sciences (2017)
22. Antibody-Drug Therapeutic Conjugates: Potential of Antibody-Sirnas in Cancer Therapy, Journal of Cellular Physiology (2019)
23. Immunopet: Antibody-Based Pet Imaging in Solid Tumors, Frontiers in Medicine (2022)
24. Nanobodies As Powerful Pulmonary Targeted Biotherapeutics Against Sars-Cov-2, Pharmaceutical Point of View, Biochimica et Biophysica Acta - General Subjects (2021)
25. Engineering an Anti-Granulocyte Colony Stimulating Factor Receptor Nanobody for Improved Affinity, Life Sciences (2020)
26. Targeting and Imaging of Her2 Overexpression Tumor With a New Peptide-Based 68Ga-Pet Radiotracer, Bioorganic Chemistry (2021)
27. Inhibition of Breast Tumor Growth and Abnormal Angiogenesis in Mice Treated With Endothelial Cells and Their Progenitor Mesenchymal Stem Cells Derived From Bone Marrow, Neoplasma (2016)
28. Liposome-Targeted Delivery for Highly Potent Drugs, Artificial Cells# Nanomedicine and Biotechnology (2017)
29. The Augmenting Effects of the Tdna Insulator on Stable Expression of Monoclonal Antibody in Chinese Hamster Ovary Cells, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy (2018)
30. Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor, Iranian Biomedical Journal (2020)
31. Development of a Met-Targeted Single-Chain Antibody Fragment As an Anti-Oncogene Targeted Therapy for Breast Cancer, Investigational New Drugs (2023)